0000899243-20-026192.txt : 20200923 0000899243-20-026192.hdr.sgml : 20200923 20200923191056 ACCESSION NUMBER: 0000899243-20-026192 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200731 FILED AS OF DATE: 20200923 DATE AS OF CHANGE: 20200923 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lubner David Charles CENTRAL INDEX KEY: 0001572000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 201193127 MAIL ADDRESS: STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC. STREET 2: 480 ARSENAL STREET, SUITE 110 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-31 0 0001818794 Dyne Therapeutics, Inc. DYN 0001572000 Lubner David Charles C/O DYNE THERAPEUTICS, INC. 830 WINTER STREET WALTHAM MA 02451 1 0 0 0 Common Stock 2020-09-21 4 C 0 53625 A 53625 D Stock Option (right to buy) 5.54 2020-07-31 4 A 0 11156 0.00 A 2030-07-30 Common Stock 11156 11156 D Stock Option (right to buy) 5.54 2020-07-31 4 A 0 14444 0.00 A 2030-07-30 Common Stock 14444 14444 D Series B Preferred Stock 2020-08-07 4 P 0 177872 2.811 A Common Stock 53625 177872 D Series B Preferred Stock 2020-09-21 4 C 0 177872 0.00 D Common Stock 53625 0 D On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to March 19, 2021. The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to March 19, 2021. The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. /s/ Richard Scalzo, Attorney-in-Fact 2020-09-23